-
1
-
-
2342466734
-
Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030
-
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
-
(2004)
Diabetes Care
, vol.27
, Issue.5
, pp. 1047-1053
-
-
Wild, S.1
Roglic, G.2
Green, A.3
Sicree, R.4
King, H.5
-
2
-
-
0034641568
-
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
-
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258): 405-412.
-
(2000)
BMJ
, vol.321
, Issue.7258
, pp. 405-412
-
-
Stratton, I.M.1
Adler, A.I.2
Neil, H.A.3
-
3
-
-
84897839568
-
Clinical and economic characteristics associated with type 2 diabetes
-
December 17, Epub ahead of print
-
Sicras-Mainar A, Navarro-Artieda R, Ibanez-Nolla J. Clinical and economic characteristics associated with type 2 diabetes. Rev Clin Esp. December 17, 2013. [Epub ahead of print.]
-
(2013)
Rev Clin Esp
-
-
Sicras-Mainar, A.1
Navarro-Artieda, R.2
Ibanez-Nolla, J.3
-
4
-
-
84864285795
-
Management of hyper-glycaemia in type 2 diabetes: A patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyper-glycaemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-1596.
-
(2012)
Diabetologia
, vol.55
, Issue.6
, pp. 1577-1596
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
5
-
-
53749096863
-
10-year follow-up of intensive glucose control in type 2 diabetes
-
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
-
(2008)
N Engl J Med
, vol.359
, Issue.15
, pp. 1577-1589
-
-
Holman, R.R.1
Paul, S.K.2
Bethel, M.A.3
Matthews, D.R.4
Neil, H.A.5
-
6
-
-
45149131667
-
Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes
-
Gerstein HC, Miller ME, Byington R P, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
-
(2008)
N Engl J Med
, vol.358
, Issue.24
, pp. 2545-2559
-
-
Gerstein, H.C.1
Miller, M.E.2
Byington, R.P.3
-
7
-
-
45149133036
-
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
-
Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
-
(2008)
N Engl J Med
, vol.358
, Issue.24
, pp. 2560-2572
-
-
Patel, A.1
Macmahon, S.2
Chalmers, J.3
-
8
-
-
58149389215
-
Glucose control and vascular complications in veterans with type 2 diabetes
-
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
-
(2009)
N Engl J Med
, vol.360
, Issue.2
, pp. 129-139
-
-
Duckworth, W.1
Abraira, C.2
Moritz, T.3
-
9
-
-
70349881450
-
Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes
-
Turnbull FM, Abraira C, Anderson RJ, et al; Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-2298.
-
(2009)
Diabetologia
, vol.52
, Issue.11
, pp. 2288-2298
-
-
Turnbull, F.M.1
Abraira, C.2
Anderson, R.J.3
-
10
-
-
12244299450
-
Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: A new analysis
-
Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005;90(1):493-500.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, Issue.1
, pp. 493-500
-
-
Ferrannini, E.1
Gastaldelli, A.2
Miyazaki, Y.3
Matsuda, M.4
Mari, A.5
Defronzo, R.A.6
-
11
-
-
0028817815
-
UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease
-
[No authors listed]
-
[No authors listed]. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249-1258.
-
(1995)
UK Prospective Diabetes Study Group. Diabetes
, vol.44
, Issue.11
, pp. 1249-1258
-
-
-
12
-
-
78650753885
-
Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications
-
Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011; 124(Suppl 1):S3-S18.
-
(2011)
Am J Med
, vol.124
, Issue.SUPPL. 1
-
-
Nauck, M.A.1
-
13
-
-
4644279733
-
Increasing prevalence of the metabolic syndrome among US adults
-
Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care. 2004;27(10): 2444-2449.
-
(2004)
Diabetes Care
, vol.27
, Issue.10
, pp. 2444-2449
-
-
Ford, E.S.1
Giles, W.H.2
Mokdad, A.H.3
-
14
-
-
77957198071
-
The metabolic syndrome and cardiovascular risk - a systematic review and meta-analysis
-
Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk - a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113-1132.
-
(2010)
J Am Coll Cardiol
, vol.56
, Issue.14
, pp. 1113-1132
-
-
Mottillo, S.1
Filion, K.B.2
Genest, J.3
-
15
-
-
33845405222
-
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
-
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
-
(2006)
N Engl J Med
, vol.355
, Issue.23
, pp. 2427-2443
-
-
Kahn, S.E.1
Haffner, S.M.2
Heise, M.A.3
-
16
-
-
79959774265
-
Therapy in the early stage: Incretins
-
Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care. 2011;34 Suppl 2:S264-S271.
-
(2011)
Diabetes Care
, vol.34
, Issue.SUPPL. 2
-
-
Cernea, S.1
Raz, I.2
-
17
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157.
-
(2007)
Gastroenterology
, vol.132
, Issue.6
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
18
-
-
0022617246
-
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
-
Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52.
-
(1986)
Diabetologia
, vol.29
, Issue.1
, pp. 46-52
-
-
Nauck, M.1
Stockmann, F.2
Ebert, R.3
Creutzfeldt, W.4
-
19
-
-
33846006173
-
The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.
-
(2006)
Lancet
, vol.368
, Issue.9548
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
20
-
-
0034108646
-
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
-
Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664-1669.
-
(2000)
J Med Chem
, vol.43
, Issue.9
, pp. 1664-1669
-
-
Knudsen, L.B.1
Nielsen, P.F.2
Huusfeldt, P.O.3
-
21
-
-
74549177233
-
A review of effcacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus
-
Montanya E, Sesti G. A review of effcacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther. 2009;31(11): 2472-2488.
-
(2009)
Clin Ther
, vol.31
, Issue.11
, pp. 2472-2488
-
-
Montanya, E.1
Sesti, G.2
-
22
-
-
10744230106
-
GLP-1 derivative liraglutide in rats with beta-cell deficiencies: Influence of metabolic state on beta-cell mass dynamics
-
Sturis J, Gotfredsen CF, Romer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: Influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol. 2003;140(1):123-132.
-
(2003)
Br J Pharmacol
, vol.140
, Issue.1
, pp. 123-132
-
-
Sturis, J.1
Gotfredsen, C.F.2
Romer, J.3
-
23
-
-
0036784675
-
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice
-
Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab. 2002;283(4): E745-E752.
-
(2002)
Am J Physiol Endocrinol Metab
, vol.283
, Issue.4
-
-
Rolin, B.1
Larsen, M.O.2
Gotfredsen, C.F.3
-
24
-
-
84860363301
-
In vitro proliferation of adult human beta-cells
-
Rutti S, Sauter NS, Bouzakri K, Prazak R, Halban PA, Donath MY. In vitro proliferation of adult human beta-cells. PLoS One. 2012;7(4): e35801.
-
(2012)
PLoS One
, vol.7
, Issue.4
-
-
Rutti, S.1
Sauter, N.S.2
Bouzakri, K.3
Prazak, R.4
Halban, P.A.5
Donath, M.Y.6
-
25
-
-
84886592674
-
Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease
-
McClean PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology. 2014;76 Pt A: 57-67.
-
(2014)
Neuropharmacology
, vol.76
, Issue.PART A
, pp. 57-67
-
-
McClean, P.L.1
Holscher, C.2
-
26
-
-
33847072735
-
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not
-
Raun K, von Voss P, Gotfredsen C F, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes. 2007;56(1):8-15.
-
(2007)
Diabetes
, vol.56
, Issue.1
, pp. 8-15
-
-
Raun, K.1
von Voss, P.2
Gotfredsen, C.F.3
Golozoubova, V.4
Rolin, B.5
Knudsen, L.B.6
-
27
-
-
1442311383
-
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
-
Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962-965.
-
(2004)
Circulation
, vol.109
, Issue.8
, pp. 962-965
-
-
Nikolaidis, L.A.1
Mankad, S.2
Sokos, G.G.3
-
28
-
-
77958052010
-
A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-infammatory action in endothelial cells
-
Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-infammatory action in endothelial cells. Diabetologia. 2010;53(10):2256-2263.
-
(2010)
Diabetologia
, vol.53
, Issue.10
, pp. 2256-2263
-
-
Hattori, Y.1
Jojima, T.2
Tomizawa, A.3
-
29
-
-
0036676385
-
Pharmacokinetics, pharma-codynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects
-
Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharma-codynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002;25(8):1398-1404.
-
(2002)
Diabetes Care
, vol.25
, Issue.8
, pp. 1398-1404
-
-
Elbrond, B.1
Jakobsen, G.2
Larsen, S.3
-
30
-
-
77955820667
-
Population phar-macokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide
-
Watson E, Jonker DM, Jacobsen LV, Ingwersen SH. Population phar-macokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. J Clin Pharmacol. 2010;50(8): 886-894.
-
(2010)
J Clin Pharmacol
, vol.50
, Issue.8
, pp. 886-894
-
-
Watson, E.1
Jonker, D.M.2
Jacobsen, L.V.3
Ingwersen, S.H.4
-
31
-
-
70849096647
-
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
-
Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68(6):898-905.
-
(2009)
Br J Clin Pharmacol
, vol.68
, Issue.6
, pp. 898-905
-
-
Jacobsen, L.V.1
Hindsberger, C.2
Robson, R.3
Zdravkovic, M.4
-
32
-
-
78049354214
-
Infuence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
-
Flint A, Nazzal K, Jagielski P, Hindsberger C, Zdravkovic M. Infuence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol. 2010;70(6):807-814.
-
(2010)
Br J Clin Pharmacol
, vol.70
, Issue.6
, pp. 807-814
-
-
Flint, A.1
Nazzal, K.2
Jagielski, P.3
Hindsberger, C.4
Zdravkovic, M.5
-
33
-
-
82455213000
-
The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen
-
Kapitza C, Zdravkovic M, Hindsberger C, Flint A. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Adv Ther. 2011;28(8):650-660.
-
(2011)
Adv Ther
, vol.28
, Issue.8
, pp. 650-660
-
-
Kapitza, C.1
Zdravkovic, M.2
Hindsberger, C.3
Flint, A.4
-
34
-
-
62449129181
-
LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
-
Marre M, Shaw J, Brandle M, et al; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268-278.
-
(2009)
Diabet Med
, vol.26
, Issue.3
, pp. 268-278
-
-
Marre, M.1
Shaw, J.2
Brandle, M.3
-
35
-
-
62449169287
-
LEAD-2 Study Group. Effcacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study
-
Nauck M, Frid A, Hermansen K, et al; LEAD-2 Study Group. Effcacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1): 84-90.
-
(2009)
Diabetes Care
, vol.32
, Issue.1
, pp. 84-90
-
-
Nauck, M.1
Frid, A.2
Hermansen, K.3
-
36
-
-
59449101432
-
LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): A randomised, 52-week, Phase III, double-blind, parallel-treatment trial
-
Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-481.
-
(2009)
Lancet
, vol.373
, Issue.9662
, pp. 473-481
-
-
Garber, A.1
Henry, R.2
Ratner, R.3
-
37
-
-
67650066860
-
LEAD-4 Study Investigators. Effcacy and safety of the human glucagon-like peptide-1 analog lira-glutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)
-
Zinman B, Gerich J, Buse JB, et al; LEAD-4 Study Investigators. Effcacy and safety of the human glucagon-like peptide-1 analog lira-glutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32(7): 1224-1230.
-
(2009)
Diabetes Care
, vol.32
, Issue.7
, pp. 1224-1230
-
-
Zinman, B.1
Gerich, J.2
Buse, J.B.3
-
38
-
-
69949117621
-
Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial
-
Russell-Jones D, Vaag A, Schmitz O, et al; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046-2055.
-
(2009)
Diabetologia
, vol.52
, Issue.10
, pp. 2046-2055
-
-
Russell-Jones, D.1
Vaag, A.2
Schmitz, O.3
-
39
-
-
67649666737
-
LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
-
Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
-
(2009)
Lancet
, vol.374
, Issue.9683
, pp. 39-47
-
-
Buse, J.B.1
Rosenstock, J.2
Sesti, G.3
-
40
-
-
77956076972
-
Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents
-
Buse JB, Sesti G, Schmidt WE, et al; Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33(6): 1300-1303.
-
(2010)
Diabetes Care
, vol.33
, Issue.6
, pp. 1300-1303
-
-
Buse, J.B.1
Sesti, G.2
Schmidt, W.E.3
-
41
-
-
77952309372
-
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial
-
1860-LIRA-DPP-4 Study Group
-
Pratley RE, Nauck M, Bailey T, et al; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724): 1447-1456.
-
(2010)
Lancet
, vol.375
, Issue.9724
, pp. 1447-1456
-
-
Pratley, R.E.1
Nauck, M.2
Bailey, T.3
-
42
-
-
2342599057
-
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes
-
Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53(5):1187-1194.
-
(2004)
Diabetes
, vol.53
, Issue.5
, pp. 1187-1194
-
-
Degn, K.B.1
Juhl, C.B.2
Sturis, J.3
-
43
-
-
69949152670
-
Liraglutide once daily human GLP-1 analog, signifcantly improves beta-cell function in subjects with type 2 diabetes
-
Mattheus D, Marre M, Le Thi TD, et al. Liraglutide once daily human GLP-1 analog, signifcantly improves beta-cell function in subjects with type 2 diabetes. Diabetes. 2008;57:A150.
-
(2008)
Diabetes
, vol.57
-
-
Mattheus, D.1
Marre, M.2
Le Thi, T.D.3
-
44
-
-
84897844630
-
Liraglutide improves two indicators of beta cell function - HOMA-B and proinsulin:Insulin ratio - in a meta-analysis of 6 clinical trials
-
Matthews DR, Vilsbøll T, Courrèges J-P, Zychma M, Falahati A, Bode B W. Liraglutide improves two indicators of beta cell function - HOMA-B and proinsulin:insulin ratio - in a meta-analysis of 6 clinical trials. Diabetologia. 2010;53 Suppl 1:S339.
-
(2010)
Diabetologia
, vol.53
, Issue.SUPPL. 1
-
-
Matthews, D.R.1
Vilsbøll, T.2
Courrèges, J.-P.3
Zychma, M.4
Falahati, A.5
Bode, B.W.6
-
45
-
-
70450150886
-
A meta- analysis of six clinical trials demonstrates that the once-daily human GLP-1 analogue liraglutide reduces systolic blood pressure
-
Fonseca V, Falahati A, Zychma M, Madsbad S, Plutzky J. A meta- analysis of six clinical trials demonstrates that the once-daily human GLP-1 analogue liraglutide reduces systolic blood pressure. Diabetologia. 2009;52 Suppl 1:S299.
-
(2009)
Diabetologia
, vol.52
, Issue.SUPPL. 1
-
-
Fonseca, V.1
Falahati, A.2
Zychma, M.3
Madsbad, S.4
Plutzky, J.5
-
46
-
-
84875218074
-
In subjects with type 2 diabetes, liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure with negligible impact from weight loss
-
Fonseca VA, Henry RR, Tabanera Y, Palacios R, Brett J, Plutzky J. In subjects with type 2 diabetes, liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure with negligible impact from weight loss. Diabetologia. 2010;53 Suppl 1:S510.
-
(2010)
Diabetologia
, vol.53
, Issue.SUPPL. 1
-
-
Fonseca, V.A.1
Henry, R.R.2
Tabanera, Y.3
Palacios, R.4
Brett, J.5
Plutzky, J.6
-
47
-
-
84860112822
-
Liraglutide, a once-daily human GLP-1 analog, lowers systolic blood pressure (SBP) independently of concomitant antihypertensive treatment
-
296-OR
-
Fonseca V, Plutzky J, Montanya E, et al. Liraglutide, a once-daily human GLP-1 analog, lowers systolic blood pressure (SBP) independently of concomitant antihypertensive treatment. Diabetes. 2010;59 Suppl 1: A79(296-OR).
-
(2010)
Diabetes
, vol.59
, Issue.SUPPL. 1
-
-
Fonseca, V.1
Plutzky, J.2
Montanya, E.3
-
48
-
-
77954743683
-
The once-daily human GLP-1 analogue, liraglutide, signifcantly reduces markers of cardiovascular risk in type 2 diabetes: A meta-analysis of six clinical trials
-
Plutzky J, Garber AJ, Falahati A, Toft AD, Poulter NR. The once-daily human GLP-1 analogue, liraglutide, signifcantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials. Eur Heart J. 2009;30 Suppl 1:917.
-
(2009)
Eur Heart J
, vol.30
, Issue.SUPPL. 1
, pp. 917
-
-
Plutzky, J.1
Garber, A.J.2
Falahati, A.3
Toft, A.D.4
Poulter, N.R.5
-
49
-
-
79952755181
-
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: A randomised, parallel-group, open-label trial
-
Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397-407.
-
(2011)
Int J Clin Pract
, vol.65
, Issue.4
, pp. 397-407
-
-
Pratley, R.1
Nauck, M.2
Bailey, T.3
-
50
-
-
79953237137
-
Thyroid cancer incidence patterns in the united states by histologic type, 1992-2006
-
Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid. 2011;21(2):125-134.
-
(2011)
Thyroid
, vol.21
, Issue.2
, pp. 125-134
-
-
Aschebrook-Kilfoy, B.1
Ward, M.H.2
Sabra, M.M.3
Devesa, S.S.4
-
51
-
-
77950228684
-
Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation
-
Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4): 1473-1486.
-
(2010)
Endocrinology
, vol.151
, Issue.4
, pp. 1473-1486
-
-
Bjerre, K.L.1
Madsen, L.W.2
Andersen, S.3
-
52
-
-
77649294607
-
Weighing risks and benefts of liraglutide - the FDA's review of a new antidiabetic therapy
-
Parks M, Rosebraugh C. Weighing risks and benefts of liraglutide - the FDA's review of a new antidiabetic therapy. N Engl J Med. 2010;362(9):774-777.
-
(2010)
N Engl J Med
, vol.362
, Issue.9
, pp. 774-777
-
-
Parks, M.1
Rosebraugh, C.2
-
53
-
-
79952284556
-
GLP-1 and calcitonin concentration in humans: Lack of evidence of calci-tonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide
-
Hegedus L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calci-tonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011;96(3): 853-860.
-
(2011)
J Clin Endocrinol Metab
, vol.96
, Issue.3
, pp. 853-860
-
-
Hegedus, L.1
Moses, A.C.2
Zdravkovic, M.3
Le Thi, T.4
Daniels, G.H.5
-
54
-
-
57649216660
-
Determination of calcitonin levels in C-cell disease: Clinical interest and potential pitfalls
-
Costante G, Durante C, Francis Z, Schlumberger M, Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab. 2009;5(1): 35-44.
-
(2009)
Nat Clin Pract Endocrinol Metab
, vol.5
, Issue.1
, pp. 35-44
-
-
Costante, G.1
Durante, C.2
Francis, Z.3
Schlumberger, M.4
Filetti, S.5
-
55
-
-
65949111736
-
Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study
-
Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32(5):834-838.
-
(2009)
Diabetes Care
, vol.32
, Issue.5
, pp. 834-838
-
-
Noel, R.A.1
Braun, D.K.2
Patterson, R.E.3
Bloomgren, G.L.4
-
56
-
-
84860577431
-
The human GLP-1 analog liraglutide and the pancreas: Evidence for the absence of structural pancreatic changes in three species
-
Nyborg NC, Molck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes. 2012;61(5): 1243-1249.
-
(2012)
Diabetes
, vol.61
, Issue.5
, pp. 1243-1249
-
-
Nyborg, N.C.1
Molck, A.M.2
Madsen, L.W.3
Knudsen, L.B.4
-
57
-
-
84863950236
-
The effects of 13 wk of lira-glutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: A quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis
-
Vrang N, Jelsing J, Simonsen L, et al. The effects of 13 wk of lira-glutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab. 2012;303(2):E253-E264.
-
(2012)
Am J Physiol Endocrinol Metab
, vol.303
, Issue.2
-
-
Vrang, N.1
Jelsing, J.2
Simonsen, L.3
-
58
-
-
84880096073
-
Assessment of acute pancreatitis in liraglutide type 2 diabetes trials
-
Jensen TM, Saha K, Steinberg W. Assessment of acute pancreatitis in liraglutide type 2 diabetes trials. Pancreas. 2012;41: 1370-1371.
-
(2012)
Pancreas
, vol.41
, pp. 1370-1371
-
-
Jensen, T.M.1
Saha, K.2
Steinberg, W.3
-
59
-
-
84897834269
-
-
EPAR summary for the public. Available from, Accessed February 24
-
European Medicines Agency; Victoza liraglutide. EPAR summary for the public. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001026/human_med_001137.jsp&mid=WC0b01ac058001d124. Accessed February 24, 2014.
-
(2014)
European Medicines Agency; Victoza Liraglutide
-
-
-
60
-
-
84878352363
-
Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors
-
Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595-2604.
-
(2013)
Diabetes
, vol.62
, Issue.7
, pp. 2595-2604
-
-
Butler, A.E.1
Campbell-Thompson, M.2
Gurlo, T.3
Dawson, D.W.4
Atkinson, M.5
Butler, P.C.6
-
61
-
-
84893813443
-
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared with other antidiabetic drugs
-
Funch D, Gydesen H, Tornoe K, Major-Pedersen A, Chan KA. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared with other antidiabetic drugs. Diabetes Obes Metab. 2014;16(3):273-275.
-
(2014)
Diabetes Obes Metab
, vol.16
, Issue.3
, pp. 273-275
-
-
Funch, D.1
Gydesen, H.2
Tornoe, K.3
Major-Pedersen, A.4
Chan, K.A.5
-
62
-
-
79956328908
-
Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: Results from the liraglutide effect and action in diabetes (LEAD) trials
-
Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the liraglutide effect and action in diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011;96(6): 1695-1702.
-
(2011)
J Clin Endocrinol Metab
, vol.96
, Issue.6
, pp. 1695-1702
-
-
Buse, J.B.1
Garber, A.2
Rosenstock, J.3
-
63
-
-
18144401971
-
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
-
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-1100.
-
(2005)
Diabetes Care
, vol.28
, Issue.5
, pp. 1092-1100
-
-
Defronzo, R.A.1
Ratner, R.E.2
Han, J.3
Kim, D.D.4
Fineman, M.S.5
Baron, A.D.6
-
64
-
-
79959692519
-
Mild renal impairment and the efficacy and safety of liraglutide
-
Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract. 2011;17(3): 345-355.
-
(2011)
Endocr Pract
, vol.17
, Issue.3
, pp. 345-355
-
-
Davidson, J.A.1
Brett, J.2
Falahati, A.3
Scott, D.4
-
65
-
-
30944452333
-
Assessing patient satisfaction: Concepts, applications, and measurement
-
Speight J. Assessing patient satisfaction: concepts, applications, and measurement. Value Health. 2005;8 Suppl 1:S6-S8.
-
(2005)
Value Health
, vol.8
, Issue.SUPPL. 1
-
-
Speight, J.1
-
66
-
-
0035257507
-
Development of a brief measure to assess quality of life in obesity
-
Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obes Res. 2001;9(2): 102-111.
-
(2001)
Obes Res
, vol.9
, Issue.2
, pp. 102-111
-
-
Kolotkin, R.L.1
Crosby, R.D.2
Kosloski, K.D.3
Williams, G.R.4
-
67
-
-
77956707365
-
Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin
-
Hermansen K, Kolotkin RL, Hammer M, Zdravkovic M, Matthews D. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. Prim Care Diabetes. 2010;4(2):113-117.
-
(2010)
Prim Care Diabetes
, vol.4
, Issue.2
, pp. 113-117
-
-
Hermansen, K.1
Kolotkin, R.L.2
Hammer, M.3
Zdravkovic, M.4
Matthews, D.5
-
68
-
-
77954184211
-
LEAD-3 Study Group. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: Results from a randomized controlled trial in patients with type 2 diabetes
-
Bode B W, Testa MA, Magwire M, et al; LEAD-3 Study Group. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(7):604-612.
-
(2010)
Diabetes Obes Metab
, vol.12
, Issue.7
, pp. 604-612
-
-
Bode, B.W.1
Testa, M.A.2
Magwire, M.3
-
69
-
-
79851495878
-
Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin
-
Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R. Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med. 2011;28(3):333-337.
-
(2011)
Diabet Med
, vol.28
, Issue.3
, pp. 333-337
-
-
Davies, M.1
Pratley, R.2
Hammer, M.3
Thomsen, A.B.4
Cuddihy, R.5
-
70
-
-
80052706196
-
-
Montanya E, Pratley R, Nauck M, et al. Switching from sitagliptin to liraglutide, in combination with metformin, improves treatment satisfaction in patients with type 2 diabetes Diabetes. 2011;60 Suppl 1: A307.
-
(2011)
Switching From Sitagliptin to Liraglutide, In Combination With Metformin, Improves Treatment Satisfaction In Patients With Type 2 Diabetes Diabetes
, vol.60
, Issue.SUPPL. 1
-
-
Montanya, E.1
Pratley, R.2
Nauck, M.3
-
71
-
-
79955950106
-
Patient-reported outcomes are superior in patients with type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: Results from a randomized, open-label study
-
Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB. Patient-reported outcomes are superior in patients with type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. Diabet Med. 2011;28(6):715-723.
-
(2011)
Diabet Med
, vol.28
, Issue.6
, pp. 715-723
-
-
Schmidt, W.E.1
Christiansen, J.S.2
Hammer, M.3
Zychma, M.J.4
Buse, J.B.5
-
72
-
-
84890571759
-
Independent glucose and weight-reducing effects of liraglutide in a real-world population of type 2 diabetic outpatients
-
Fadini G P, Simioni N, Frison V, et al. Independent glucose and weight-reducing effects of liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetol. 2013;50(6):943-949.
-
(2013)
Acta Diabetol
, vol.50
, Issue.6
, pp. 943-949
-
-
Fadini, G.P.1
Simioni, N.2
Frison, V.3
-
73
-
-
83655184782
-
1c of,7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme
-
Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of,7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14(1):77-82.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.1
, pp. 77-82
-
-
Zinman, B.1
Schmidt, W.E.2
Moses, A.3
Lund, N.4
Gough, S.5
-
74
-
-
84897836468
-
ABCD Nationwide Liraglutide Audit Contributors. Liraglutide is effective across a range of obese body mass indices; fndings from the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit
-
October 1-5, Berlin, Germany
-
Ryder REJ, Sen-Gupta P, Thong KY; ABCD Nationwide Liraglutide Audit Contributors. Liraglutide is effective across a range of obese body mass indices; fndings from the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit. Poster 801 presented at the 2012 meeting of the European Association for the Study of Diabetes, October 1-5, 2012, Berlin, Germany.
-
(2012)
Poster 801 Presented At the 2012 Meeting of the European Association For the Study of Diabetes
-
-
Ryder, R.E.J.1
Sen-Gupta, P.2
Thong, K.Y.3
|